• 1
    Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 41722.
  • 2
    Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut 1987; 28: 4105.
  • 3
    Pigot F, Roux C, Chaussade S, et al. Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci 1992; 37: 1396403.
  • 4
    Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn’s disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7: 60914.
  • 5
    Scharla SH, Minne HW, Lempert UG, et al. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Exp Clin Endocrinol 1994; 102: 449.
  • 6
    Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997; 32: 124755.
  • 7
    Deal CL. Osteoporosis: prevention, diagnosis, and management. Am J Med 1997; 102: S359.
  • 8
    Jahnsen J, Falch JA, Aadland E, Mowinckel P. Bone mineral density is reduced in patients with Crohn’s disease but not in patients with ulcerative colitis: a population based study. Gut 1997; 40: 3139.
  • 9
    Eastell R & Blumsohn A. The value of biochemical markers of bone turnover in osteoporosis. J Rheumatol 1997; 24: 12157.
  • 10
    Bischoff SC, Herrmann A, Goke M, Manns MP, Von-zur MA, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997; 92: 115763.
  • 11
    Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 1997; 40: 22833.
  • 12
    Silvennoinen J, Risteli L, Karttunen T, Risteli J. Increased degradation of type I collagen in patients with inflammatory bowel disease. Gut 1996; 38: 2238.
  • 13
    Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: 26875.
  • 14
    D'Haens G, Verstraete A, Cheyns K, Aerden I, Bouillon R, Rutgeerts P. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn’s disease. Aliment Pharmacol Ther 1998; 12: 41924.DOI: 10.1046/j.1365-2036.1998.00321.x
  • 15
    Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol 2000; 95: 699704.
    Direct Link:
  • 16
    Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi PG. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn’s disease and ulcerative colitis. J Intern Med 2000; 247: 6370.DOI: 10.1046/j.1365-2796.2000.00582.x
  • 17
    Dinca M, Fries W, Luisetto G, et al. Evolution of osteopenia in inflammatory bowel disease. Am J Gastroenterol 1999; 94: 12927.
    Direct Link:
  • 18
    Roux C, Abitbol V, Chaussade S, et al. Bone loss in patients with inflammatory bowel disease: a prospective study. Osteoporos Int 1995; 5: 15660.
  • 19
    Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 20000; 119: 12038.
  • 20
    Martin A, Fries W, Luisetto G, et al. Bone density and calcium metabolism in patients with long-standing quiescent Crohn’s disease. Eur J Gastroenterol Hepatol 1994; 6: 6116.
  • 21
    Robinson RJ, Iqbal SJ, Abrams K, Al Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn’s disease. Aliment Pharmacol Ther 1998; 12: 699705.DOI: 10.1046/j.1365-2036.1998.00364.x
  • 22
    Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr 1997; 24: 28995.
  • 23
    Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 170(Suppl.): 26.
  • 24
    Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 43944.
  • 25
    Baecke JA, Burema J, Frijters JE. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982; 36: 93642.
  • 26
    Garnero P & Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993; 77: 104653.
  • 27
    Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994; 40: 20225.
  • 28
    Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995; 80: 8648.
  • 29
    Robins SP, Woitge H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994; 9: 16439.
  • 30
    Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL. Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 1993; 39: 52933.
  • 31
    Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy X-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 1990; 51: 110612.
  • 32
    Mazess RB, Barden HS, Ettinger M, et al. Spine and femur density using dual-photon absorptiometry in US white women. Bone Miner 1987; 2: 2119.
  • 33
    Stevenson JC, Lees B, Devenport M, Cust MP, Ganger KF. Determinants of bone density in normal women: risk factors for future osteoporosis? Br Med J 1989; 298: 9248.
  • 34
    Kroger H, Heikkinen J, Laitinen K, Kotaniemi A. Dual-energy X-ray absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers. Osteoporos Int 1992; 2: 13540.
  • 35
    Anon. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organisation Technical Report Series 1994; 843: 1129.
  • 36
    Croucher PI, Vedi S, Motley RJ, Garrahan NJ, Stanton MR, Compston JE. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporos Int 1993; 3: 23641.
  • 37
    Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11: 15318.
  • 38
    Melton LJ III, Khosla S, Atkinson EJ, et al. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997; 12: 108391.
  • 39
    Riggs BL, Melton LJ III, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996; 18: S197201.
  • 40
    Riggs BL. Are biochemical markers for bone turnover clinically useful for monitoring therapy in individual osteoporotic patients? Bone 2000; 26: 5512.
  • 41
    Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 1998; 13: 793802.
  • 42
    Manolagas SC & Weinstein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 1999; 14: 10616.
  • 43
    Teichmann J, Lange U, Stracke H, Doppl W, Klor HU, Federlin K. Rapid spinal trabecular bone loss in female patients with ileitis terminalis Crohn and additional sacroiliac joint inflammation. Rheumatol Int 1997; 17: 458.
  • 44
    Von Tirpitz C, Klaus J, Bruckel J, et al. Increase of bone mineral density with sodium fluoride in patients with Crohn’s disease. Eur J Gastroenterol Hepatol 2000; 12: 1924.
  • 45
    Lips P. Fluoride in osteoporosis: still an experimental and controversial treatment. Ned Tijdschr Geneeskd 1998; 142: 19135.
  • 46
    Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104: 136374.
  • 47
    Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease. Gastroenterology 2000; 119: 63946.